Novel non-steroidal aromatase inhibitors

Are there new perspectives in the treatment of breast cancer?

Emilio Bajetta, Luigi Celio, Roberto Buzzoni, Ettore Bichisao

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Breast cancer is the most common malignant neoplasm affecting women in Western countries, and most new cases are manifested during the postmenopausal period. The clinical results obtained with aminoglutethimide, and later with formestane, have established aromatase inhibition as one of the major therapeutic options in hormone-dependent advanced disease. Nevertheless, the lack of specificity of aminoglutethimide and the less than optimal oral activity of formestane soon led to further efforts to find a potent, highly selective, orally active, side-effect-free aromatase inhibitor for use in postmenopausal women with advanced breast cancer. Here we review the available data on three new, competitive non-steroidal aromatase inhibitors - letrozole, vorozole and anastrozole - which are approaching the point of detailed pharmacologic and clinical evaluation. Preliminary data have confirmed the high potency and selectivity of these endocrine agents, but their antitumor activity still remains to be completely defined. Challenges given by these novel aromatase inhibitors are discussed taking into account the biologic implications related to their mechanism of action and their future use in the management of breast cancer.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalTumori
Volume82
Issue number5
Publication statusPublished - Sep 1996

Fingerprint

Aromatase Inhibitors
Aminoglutethimide
letrozole
Breast Neoplasms
vorozole
Postmenopause
Aromatase
Antineoplastic Agents
Therapeutics
Hormones
Neoplasms
formestane

Keywords

  • advanced breast cancer
  • aromatase inhibitors
  • endocrine therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Novel non-steroidal aromatase inhibitors : Are there new perspectives in the treatment of breast cancer? / Bajetta, Emilio; Celio, Luigi; Buzzoni, Roberto; Bichisao, Ettore.

In: Tumori, Vol. 82, No. 5, 09.1996, p. 417-422.

Research output: Contribution to journalArticle

@article{09832605fb6241d8821fbc6d5c5d4e0c,
title = "Novel non-steroidal aromatase inhibitors: Are there new perspectives in the treatment of breast cancer?",
abstract = "Breast cancer is the most common malignant neoplasm affecting women in Western countries, and most new cases are manifested during the postmenopausal period. The clinical results obtained with aminoglutethimide, and later with formestane, have established aromatase inhibition as one of the major therapeutic options in hormone-dependent advanced disease. Nevertheless, the lack of specificity of aminoglutethimide and the less than optimal oral activity of formestane soon led to further efforts to find a potent, highly selective, orally active, side-effect-free aromatase inhibitor for use in postmenopausal women with advanced breast cancer. Here we review the available data on three new, competitive non-steroidal aromatase inhibitors - letrozole, vorozole and anastrozole - which are approaching the point of detailed pharmacologic and clinical evaluation. Preliminary data have confirmed the high potency and selectivity of these endocrine agents, but their antitumor activity still remains to be completely defined. Challenges given by these novel aromatase inhibitors are discussed taking into account the biologic implications related to their mechanism of action and their future use in the management of breast cancer.",
keywords = "advanced breast cancer, aromatase inhibitors, endocrine therapy",
author = "Emilio Bajetta and Luigi Celio and Roberto Buzzoni and Ettore Bichisao",
year = "1996",
month = "9",
language = "English",
volume = "82",
pages = "417--422",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Novel non-steroidal aromatase inhibitors

T2 - Are there new perspectives in the treatment of breast cancer?

AU - Bajetta, Emilio

AU - Celio, Luigi

AU - Buzzoni, Roberto

AU - Bichisao, Ettore

PY - 1996/9

Y1 - 1996/9

N2 - Breast cancer is the most common malignant neoplasm affecting women in Western countries, and most new cases are manifested during the postmenopausal period. The clinical results obtained with aminoglutethimide, and later with formestane, have established aromatase inhibition as one of the major therapeutic options in hormone-dependent advanced disease. Nevertheless, the lack of specificity of aminoglutethimide and the less than optimal oral activity of formestane soon led to further efforts to find a potent, highly selective, orally active, side-effect-free aromatase inhibitor for use in postmenopausal women with advanced breast cancer. Here we review the available data on three new, competitive non-steroidal aromatase inhibitors - letrozole, vorozole and anastrozole - which are approaching the point of detailed pharmacologic and clinical evaluation. Preliminary data have confirmed the high potency and selectivity of these endocrine agents, but their antitumor activity still remains to be completely defined. Challenges given by these novel aromatase inhibitors are discussed taking into account the biologic implications related to their mechanism of action and their future use in the management of breast cancer.

AB - Breast cancer is the most common malignant neoplasm affecting women in Western countries, and most new cases are manifested during the postmenopausal period. The clinical results obtained with aminoglutethimide, and later with formestane, have established aromatase inhibition as one of the major therapeutic options in hormone-dependent advanced disease. Nevertheless, the lack of specificity of aminoglutethimide and the less than optimal oral activity of formestane soon led to further efforts to find a potent, highly selective, orally active, side-effect-free aromatase inhibitor for use in postmenopausal women with advanced breast cancer. Here we review the available data on three new, competitive non-steroidal aromatase inhibitors - letrozole, vorozole and anastrozole - which are approaching the point of detailed pharmacologic and clinical evaluation. Preliminary data have confirmed the high potency and selectivity of these endocrine agents, but their antitumor activity still remains to be completely defined. Challenges given by these novel aromatase inhibitors are discussed taking into account the biologic implications related to their mechanism of action and their future use in the management of breast cancer.

KW - advanced breast cancer

KW - aromatase inhibitors

KW - endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=0030480630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030480630&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 417

EP - 422

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -